Scientists from Cologne and Amsterdam have discovered the mutations in human genetics, which cause the hereditary disease ponto cerebellar hypoplasia (PCH) of the types 2 and 4.
“In the case of PCH, the protein complex – the so-called tRNA-Splicing-Endonuclease, is mutated. This complex in involved in the manufacture of proteins in the human body and was identified in connection with a disease for the first time,” reports Birgit Budde from the Cologne Center for Genomics and Institute for Genetics of the University of Cologne.
The disease PCH occurs when certain areas of the brain do not develop properly; this results in severe mental and physical developmental disorders. Life expectancy of those affected ranges from a few months to a few years. PCH2 was first described as a syndrome in 1990 with reference to persons affected who came from the Dutch fishing village Volendam.
Due to historical reasons, the village became isolated and remained so over centuries; the inhabitants began to marry close relatives. This resulted in a conspicuously high amount of cases of the illness in this village, as PCH usually only occurs, when both parents pass on the predisposition for this disease. Families from Volendam were the starting point for the present study.
In the mean time, cases of the disease have been discovered in other parts of Europe. Based on these, scientists have been able to prove that the majority of the cases of PCH2, including those of the village of Volendam, have a common ancestor. This common ancestor lived during the 17th century. The results of the most recent research will be published in the renowned magazine Nature Genetics. “The identification of mutations, which cause PCH2 and PCH4, is an important step in the research of ponto cerebellar hypoplasia,” according to Dr. Budde.
Patrick Honecker | Source: alphagalileo
Further information: www.uni-koeln.de
www.ccg.uni-koeln.de/
Further Reports about: cerebellar hypoplasia > discovered > Disease > Genetics > hereditary disease PCH > mutations > PCH > PCH2 > tRNA-Splicing-Endonuclease
More articles from Life Sciences:
New cancer target for non-Hodgkin's lymphoma
24.11.2009 | New York- Presbyterian Hospital/Weill Cornell Medical Center/Weill Cornell Medical College
New hydrogen-storage method discovered
24.11.2009 | Carnegie Institution
Daycare may double TV time for young children
24.11.2009 | Studies and Analyses
Insomnia prevalent among cancer patients who receive chemotherapy
24.11.2009 | Studies and Analyses
24.11.2009 | Social Sciences
Multidisciplinary meeting on Urological Cancers aims to benefit cancer patients
20.11.2009 | Event News
'Golden Age' for clinical psychology in Northern Ireland
20.11.2009 | Event News
New Perspectives in Marine Anti-Fouling Research
11.11.2009 | Event News